Find your ideal API manufacturing partner in high-growth markets globally List available now!

Lescol Xl Patent Expiration

Lescol Xl is a drug owned by Sandoz Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 13, 2020. Details of Lescol Xl's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6242003

(Pediatric)

Organic compounds
Oct, 2020

(4 years ago)

Expired
US6242003 Organic compounds
Apr, 2020

(4 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Lescol Xl is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lescol Xl's family patents as well as insights into ongoing legal events on those patents.

Lescol Xl's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Lescol Xl's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 13, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Lescol Xl Generic API suppliers:

Fluvastatin Sodium is the generic name for the brand Lescol Xl. 5 different companies have already filed for the generic of Lescol Xl, with Mylan Pharms Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lescol Xl's generic

How can I launch a generic of Lescol Xl before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Lescol Xl's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Lescol Xl's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Lescol Xl -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
80 mg 15 Mar, 2007 1 13 Apr, 2020 Extinguished





About Lescol Xl

Lescol Xl is a drug owned by Sandoz Inc. Lescol Xl uses Fluvastatin Sodium as an active ingredient. Lescol Xl was launched by Sandoz in 2000.

Approval Date:

Lescol Xl was approved by FDA for market use on 06 October, 2000.

Active Ingredient:

Lescol Xl uses Fluvastatin Sodium as the active ingredient. Check out other Drugs and Companies using Fluvastatin Sodium ingredient

Dosage:

Lescol Xl is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 80MG BASE TABLET, EXTENDED RELEASE Prescription ORAL